Compass Therapeutics/$CMPX
About Compass Therapeutics
Ticker
Industry
Employees
CMPX Metrics
$268M
-
-$0.35
0.75
-
Price and volume
Market cap
$268M
Beta
0.75
52-week high
$2.68
52-week low
$0.77
Average daily volume
1.4M
Financial strength
Current ratio
31.838
Quick ratio
30.544
Long term debt to equity
4.567
Total debt to equity
4.969
Management effectiveness
Return on assets (TTM)
-21.71%
Return on equity (TTM)
-32.00%
Valuation
Price to revenue (TTM)
310.065
Price to book
1.94
Price to tangible book (TTM)
1.94
Price to free cash flow (TTM)
-5.479
Growth
Earnings per share change (TTM)
8.50%
3-year earnings per share growth (CAGR)
-37.28%
What the Analysts think about CMPX
Analyst Ratings
CMPX Financial Performance
Income Statement
Q3 24
QoQ growth
$37B
-39.75%
$45B
107.52%
37.65%
6.78%
CMPX Earnings Performance
Earnings per share (EPS)
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
$3.69
$2.85
$2.45
$2.42
-
$3.55
$2.61
$2.05
$2.31
$3.94
3.94%
9.20%
19.51%
4.63%
-
CMPX News
Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer
Compass Therapeutics: Near-Term Readout, But Beware The High Stakes In Biliary Cancer
Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
FAQs
What’s the current market cap for Compass Therapeutics stock?
What is the P/E ratio for Compass Therapeutics stock?
Does Compass Therapeutics stock pay dividends?
No, Compass Therapeutics (CMPX) stock does not pay dividends to its shareholders as of January 15, 2025.
When is the next Compass Therapeutics dividend payment date?
Compass Therapeutics (CMPX) stock does not pay dividends to its shareholders.
What is the beta indicator for Compass Therapeutics?
Compass Therapeutics (CMPX) has a beta rating of 0.75. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.